Elicio Therapeutics (ELTX) Registration Filing summary

Company overview and business model

• Clinical-stage biotechnology company developing immunotherapies for cancer and infectious diseases using proprietary Amphiphile (AMP) technology to target lymph nodes and generate robust T cell responses.

• Pipeline includes ELI-002 (Phase 2, mutant KRAS cancers), ELI-007 (preclinical, BRAF-driven cancers), and ELI-008 (preclinical, p53-mutated cancers).

• Employs an “off-the-shelf” cancer vaccine approach using known neoantigens, aiming to provide rapid treatment options.

• Resulted from a 2023 merger with Angion Biomedica Corp., now operating as Elicio Therapeutics, Inc.

Financial performance and metrics

• As of March 31, 2024, net tangible book value was $0.48 per share; after the offering, as adjusted, $2.81 per share.

• Immediate dilution to new investors is estimated at $4.70 per share if shares are sold at $7.51 per share.

• Significant number of stock options and pre-funded warrants outstanding, with further dilution possible from future issuances.

Use of proceeds and capital allocation

• Net proceeds intended for research and clinical development of current or additional product candidates, with the remainder for working capital and general corporate purposes.

• Management retains broad discretion over allocation; proceeds may also be invested in short-term, investment-grade instruments pending use.